Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Get Free Report) was the recipient of some unusual options trading on Wednesday. Traders bought 4,063 put options on the stock. This is an increase of ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

For the mountaineers, climbing the peaks of Mount Everest is the piece de resistance of their careers. What a lot of people don't realize is that accomplishing ...

Xenon has promising Phase 2 data for MDD treatment, robust financials, and a potential in niche markets, despite premium ...

Christopher Von Seggern stepped down as Chief Commercial Officer of Xenon Pharmaceuticals Inc. and departed from the company. In connection with his departure ...

Assenagon Asset Management S.A. raised its position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Free Report) by 12.4% during the 4th quarter, HoldingsChannel reports. The fund owned 238,522 shares of ...

A group of mountaineers plan to travel from Heathrow to the summit of Mount Everest and back in just seven days - a feat ...

“Things are changing in high-altitude mountaineering and if we don’t get involved at the forefront, someone else will,” adds ...

adding to the already significant number on the "climbing Mount Everest" price tag. For another, xenon has been on the list of World Anti-Doping Agency since 2014 after reports of it being used at ...

Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a $3 billion market cap pharmaceutical company specializing in the development of therapeutic drugs, announced today the departure of its Chief Commercial ...

American scientists found inhaling xenon boosted brain health and improved problem-solving skills, which could potentially ...